The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Continuous Subcutaneous Insulin Infusion at 25 Years
Open accessAbstract
Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic subjects to achieve strict blood glucose control. A quarter of a century after its introduction, world-wide use of CSII is increasing. We review the evidence base that justifies this increase, including effectiveness compared with modern intensified insulin injection regimens and concern about possible complications. Review of controlled trials shows that, in most patients, mean blood glucose concentrations and glycated hemoglobin percentages are either slightly lower or similar on CSII versus multiple insulin injections. However, hypoglycemia is markedly less frequent than during intensive injection therapy. Ketoacidosis occurs at the same rate. Nocturnal glycemic control is improved with insulin pumps, and automatic basal rate changes help to minimize a prebreakfast blood glucose increase (the “dawn phenomenon”) often seen with injection therapy. Patients with “brittle” diabetes characterized by recurrent ketoacidosis are often not improved by CSII, although there may be exceptions. We argue that explicit clinical indications for CSII are helpful; we suggest the principal indications for health service or health insurance–funded CSII should include frequent, unpredictable hypoglycemia or a marked dawn phenomenon, which persist after attempts to improve control with intensive insulin injection regimens. In any circumstances, candidates for CSII must be motivated, willing and able to undertake pump therapy, and adequately psychologically stable. Some diabetic patients with well-defined clinical problems are likely to benefit substantially from CSII and should not be denied a trial of the treatment. Their number is relatively small, as would therefore be the demand on funds set aside for this purpose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pickup, J. C., & Williams, G. H. (1991) · Cited by 571
Self-citationContinuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.
Pickup, J. C., Keen, H., Parsons, J. A., & Alberti, K. G. (1978) · BMJ · doi:10.1136/bmj.1.6107.204 · Cited by 563
Self-citationBoland, E. A., Grey, M., Oesterle, A., Fredrickson, L., & Tamborlane, W. V. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1779 · Cited by 432
Tamborlane, W. V., Sherwin, R. S., Genel, M., & Felig, P. (1979) · New England Journal of Medicine · doi:10.1056/nejm197903153001101 · Cited by 411
Insulin analogues and their potential in the management of diabetes mellitus
Bolli, G. B., Di Marchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 349
Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Ganes, T., Kierulf, P., Smeland, E., Sandvik, L., & Aagenaes, O. (1986) · BMJ · doi:10.1136/bmj.293.6556.1195 · Cited by 329
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Insulin Lispro in CSII: Results of a Double-Blind Crossover Study
Zinman, B., Tildesley, H., Chiasson, J.-L., Tsui, E., & Strack, T. (1997) · Diabetes · doi:10.2337/diab.46.3.440 · Cited by 258
Bode, B. W., Steed, R. D., & Davidson, P. C. (1996) · Diabetes Care · doi:10.2337/diacare.19.4.324 · Cited by 257
Campbell, P. J., Bolli, G. B., Cryer, P. E., & Gerich, J. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122302 · Cited by 218
Cited by
Artificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Continuous glucose monitoring and closed‐loop systems
Hovorka, R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01672.x · Cited by 443
Closed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342
Advances in transdermal insulin delivery
Zhang, Y., Yu, J., Kahkoska, A. R., Wang, J., Buse, J. B., & Gu, Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.006 · Cited by 325
Sensor-Augmented Insulin Pump Therapy: Results of the First Randomized Treat-to-Target Study
Hirsch, I. B., Abelseth, J., Bode, B. W., Fischer, J. S., Kaufman, F. R., Mastrototaro, J., Parkin, C. G., Wolpert, H. A., & Buckingham, B. A. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0068 · Cited by 297
The Discovery of Insulin: An Important Milestone in the History of Medicine
Vecchio, I., Tornali, C., Bragazzi, N. L., & Martini, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00613 · Cited by 272
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Hovorka, R., Kumareswaran, K., Harris, J., Allen, J. M., Elleri, D., Xing, D., Kollman, C., Nodale, M., Murphy, H. R., Dunger, D. B., et al. (2011) · BMJ · doi:10.1136/bmj.d1855 · Cited by 244
“Insulin pumps are designed to mimic physiological delivery of insulin, with pre-meal doses determined according to the carbohydrate content of a planned meal, glucose levels from finger stick testing, and insulin sensitivity factors.”
BackgroundSafety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes
Plotnick, L. P., Clark, L. M., Brancati, F. L., & Erlinger, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1142 · Cited by 216
Hirsch, I. B., Bode, B. W., Garg, S., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.3.533 · Cited by 197
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
Bode, B. W. (2011) · Endocrine Practice · doi:10.4158/ep10260.ra · Cited by 56
Thethi, T. K., Rao, A., Kawji, H., Mallik, T., Yau, C. L., Christians, U., & Fonseca, V. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.03.002 · Cited by 53
Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007
Guilhem, I., Balkau, B., Lecordier, F., Malécot, J.-M., Elbadii, S., Leguerrier, A.-M., Poirier, J.-Y., Derrien, C., & Bonnet, F. (2009) · Diabetologia · doi:10.1007/s00125-009-1549-7 · Cited by 46
“However, these findings were not confirmed in most subsequent studies [4, 5].”
ResultLlewellyn, S., Procter, R., Harvey, G., Maniatopoulos, G., & Boyd, A. (2014) · Health Services and Delivery Research · doi:10.3310/hsdr02230 · Cited by 43
McTavish, L., Corley, B., Weatherall, M., Wiltshire, E., & Krebs, J. D. (2018) · Diabetic Medicine · doi:10.1111/dme.13576 · Cited by 34
Continuous subcutaneous insulin infusion: practical issues
Saboo, B., & Talaviya, P. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104055 · Cited by 32
“[13] Insulin pump therapy is contraindicated in patients lacking the commitment or competence to perform basic diabetes self-management behaviors;[6] however, many of recent research has shown that such patients can see positive results from using a pump.”
BackgroundMethodKalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Taleb, N., Messier, V., Ott-Braschi, S., Ardilouze, J.-L., & Rabasa-Lhoret, R. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.035 · Cited by 25
Metadata
- Authors
- Pickup, J., & Keen, H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 25
- Issue
- 3
- Pages
- 593-598
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2108808416
- Cited by
- 397
- References
- 50
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.